Seladelpar

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Seladelpar

CAS No. : 851528-79-5

MCE 国际站：Seladelpar

产品活性：Seladelpar (MBX-8025) 是一种有效的，具有口服活性的， 特异性 PPAR-δ 激动剂，EC₅₀ 为 2 nM。

研究领域：Cell Cycle/DNA Damage  |  Vitamin D Related/Nuclear Receptor

作用靶点：PPAR

In Vitro: Seladelpar (MBX-8025) is an orally active, potent (2 nM), and specific (>750-fold and >2500-fold compared with PPAR-α or PPAR-γ receptors, respectively) PPAR-δ agonist being developed as a lipid-altering agent. Seladelpar is a potent, and selective PPAR-δ agonist (50% effect concentration human PPAR-δ=2 nM, PPAR-α=1,600 nM) that demonstrates favorable effects on insulin resistance, diabetes, and atherogenic dyslipidemia.

In Vivo: From weaning, female Alms1 mutant (foz/foz) mice and wild-type littermates are fed an atherogenic diet for 16 weeks; groups (n=8-12) are then randomized to receive Seladelpar (10 mg/kg) or vehicle (1% methylcellulose) by gavage for 8 weeks. Despite minimally altering body weight, Seladelpar normalizes hyperglycemia, hyperinsulinemia, and glucose disposal in foz/foz mice. Serum alanine aminotransferase ranges 300-600 U/L in vehicle-treated foz/foz mice; Seladelpar reduces alanine aminotransferase by 50%. In addition, Seladelpar normalizes serum lipids and hepatic levels of free cholesterol and other lipotoxic lipids that are increased in vehicle-treated foz/foz versus wild-type mice. This abolished hepatocyte ballooning and apoptosis, substantially reduce steatosis and liver inflammation, and improve liver fibrosis. In vehicle-treated foz/foz mice, the mean nonalcoholic fatty liver disease activity score is 6.9, indicating nonalcoholic steatohepatitis (NASH); Seladelpar reverses NASH in all foz/foz mice (nonalcoholic fatty liver disease activity score 3.13). In atherogenic diet-fed Wt mice, administration of Seladelpar reduces body weight by ∼18% (P<0.05). In contrast, Seladelpar produces minimal effect on body weight in atherogenic diet–fed foz/foz mice. These animals develope severe hyperglycemia, hyperinsulinemia, and whole-body insulin resistance after 16 weeks (P<0.05); Seladelpar strikingly improves these indices (P<0.05). After intraperitoneal glucose injection, blood glucose reaches ~32 mM in vehicle-treated versus ~14 mM in Seladelpar-treated foz/foz mice (P<0.05); the area under the blood glucose disappearance curve is correspondingly lower in Seladelpar-treated foz/foz mice (P<0.05). Seladelpar produces a proportionally similar effect on glucose handling in atherogenic diet–fed Wt mice (P<0.05).

相关产品：Retinoic acid  |  Rosiglitazone  |  GW9662  |  Pioglitazone  |  Fenofibrate  |  GW6471  |  Fisetin  |  T0070907  |  Pirinixic acid  |  5-Aminosalicylic Acid  |  Troglitazone  |  GW 501516  |  Daidzein  |  Icariin  |  Astaxanthin  |  Lanifibranor  |  GW7647  |  Bezafibrate  |  Gemfibrozil 1-O-β-glucuronide  |  Elafibranor  |  GW1929  |  MK-886  |  GSK0660  |  GW0742  |  Glabridin  |  GSK3787  |  FH535  |  Magnolol  |  Candesartan  |  Gemfibrozil

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds